CureVac Acquisition Nears Critical Shareholder Vote

The proposed multi-billion euro acquisition of CureVac by BioNTech enters its final phase with two crucial November deadlines approaching. Shareholders face a pivotal decision that could see the Tübingen-based biotech firm become a permanent component of the mRNA giant.

Financial Capacity Demonstrated in SEC Filing

BioNTech moved to reassure CureVac investors regarding its financial capability to complete the acquisition through a recent SEC filing. Submitted on November 12, this supplemental prospectus reveals BioNTech generated €1.96 billion in revenue during the first nine months of 2025 while reporting a net loss of €831 million. Despite this loss, the Mainz-based company maintains substantial liquidity with €16.7 billion available in cash and marketable securities.

This document, which received approval from Germany’s BaFin financial authority, updates the original October 20 prospectus and aims to provide confidence in BioNTech’s ability to finance both the acquisition and subsequent development of CureVac’s mRNA pipeline.

Countdown to Decision: Key Dates for Investors

Two specific dates in November will determine the outcome of this potential merger:

Should investors sell immediately? Or is it worth buying CureVac?

• November 25, 2025: An extraordinary general meeting where shareholders will cast their final vote on the proposed merger and corporate restructuring
• November 14, 2025: The expiration date for withdrawal rights under the share exchange offer

The acquisition terms propose a straight share-for-share exchange, with CureVac stockholders receiving newly issued American Depositary Shares (ADSs) of BioNTech in return for their current holdings. This strategic move aims to strengthen BioNTech’s dominant position within the mRNA sector, particularly in cancer immunotherapy development.

Industry Consolidation Amid Operational Challenges

First announced in June 2025, this potential acquisition represents significant consolidation within the competitive mRNA therapeutics landscape. CureVac continues developing candidates targeting glioblastoma and non-small cell lung cancer but has yet to commercialize any products successfully. The company recently converted its restructured partnership with GSK into a licensing arrangement.

Market analysts remain cautious in their assessment, with most currently maintaining “Hold” ratings on CureVac stock. Further financial insight will arrive around November 18 when CureVac releases its third-quarter results, with industry experts anticipating another quarterly loss. The convergence of acquisition pressures, ongoing financial underperformance, and critical shareholder decisions creates a tense environment for the company in the coming weeks.